COR

Cencora Inc presents a distinctive fundamental profile among healthcare distributors, with systematic screening highlighting an exceptional 115.93% return on equity that significantly exceeds typical pharmaceutical distribution benchmarks. This elevated ROE reflects the capital-light operational model characteristic of the sector, though the company's price-to-book ratio of 40.18 indicates substantial goodwill and intangible assets on the balance sheet relative to tangible equity base of $7.78 per share.

The company's profitability structure reveals typical wholesale distribution economics, with a gross margin of 3.81% compressing to an operating margin of 0.85% and net margin of 0.78%. Despite these thin margins, Cencora generated trailing twelve-month earnings of $13.03 per share, translating to a P/E ratio of 19.67. Notably, EPS growth accelerated 51.28% year-over-year, substantially outpacing the more modest 5.95% revenue expansion, suggesting margin improvement initiatives or share count reduction.

Key strengths from a screening perspective include:

• Defensive beta of 0.62 positioning the equity as lower-volatility within healthcare exposure
• Return on investment of 22.65% demonstrating efficient capital deployment in distribution infrastructure
• Scale advantages in a concentrated oligopoly alongside peers MCK and CAH

Risk factors the model identifies:

• Elevated debt-to-equity ratio of 5.08 reflecting significant financial leverage
• Current ratio of 0.9 indicating working capital constraints typical in high-turnover distribution
• Current price near the lower end of its 52-week range ($244.82–$377.54), down approximately 31% from peak levels

Relative to McKesson and Cardinal Health, Cencora's valuation metrics at 0.15x price-to-sales position the security within the peer distribution framework for institutional portfolio construction.